CDSCO gives approval for this Anti-diabetic drug

Studies show that the prevalence of CKD in India is estimated to be 17.2 percent and nearly 10 Million patients may be on stage 4 CKD.

300
CDSCO DCGI FDA

Last Updated on November 30, 2022 by The Health Master

AstraZeneca India, a science-led biopharmaceutical company, announced that the company has received the Central Drugs Standard Control Organization’s (CDCSCO) approval for their anti-diabetic drug Dapagliflozin in the treatment of adults with chronic kidney disease (CKD).

According to the pharma major, Dapagliflozin is the first and only anti-diabetic drug approved to significantly reduce the risk of sustained eGFR (estimated glomerular filtration rate), cardiovascular deaths, and hospitalizations due to heart failure in adults with progressive chronic kidney disease.

This approval is applicable for both diabetic and non-diabetic CKD patients.

“The approval is based on the consistent results from the DAPA-CKD study, where the indication has now been recommended in adults with chronic kidney disease, up to an eGFR greater than or equal to 25 ml per minute per 1.73 m2.

Below this, the initiation is currently not recommended, however, patients may continue with their daily dose of 10mg orally to reduce the risk of eGFR decline, End Stage Kidney Disease (ESKD), cardiovascular deaths, and heart failures.

Earlier only up to CKD stage 3 patients could be initiated Dapagliflozin but with this approval, physicians can initiate Dapagliflozin for a subset of CKD stage 4,” the company said in a statement.

Chronic kidney disease (CKD) is one of the leading causes of hospitalization globally and in India, representing a significant clinical and economic burden.

CKD is a progressive disease and continues to be the major cause of morbidity and mortality, with adverse outcomes of kidney failure and premature death.

Studies show that the prevalence of CKD in India is estimated to be 17.2 percent and nearly 10 Million patients may be on stage 4 CKD.

AstraZeneca’s Dapagliflozin is an oral anti-diabetes drug that has shown increasing benefits in not only preventing heart failure but also in managing chronic kidney disease and Heart failure with reduced ejection fraction irrespective of Diabetes status, the company claims.

“The timely approval of Dapagliflozin from the CDCSCO committee with the additional indication is a huge boost for nephrologists across the country towards the management of progressive Chronic Kidney Disease.

At AstraZeneca, we are committed to constantly pushing the boundaries of science and technology to address the unmet need for heart failures and CKDs globally.

Today, there is a paradigm shift in the usage of leading diabetic drugs for a wider scope and we see huge potential for this segment.

The approval will provide the clinical community with a potential therapeutic option to arrest the progression of CKDs and address heart failures at an early stage,” Dr. Anil Kukreja, Vice President – Medical Affairs and Regulatory, AstraZeneca India said in a statement.

CDSCO gives nod to Dapagliflozin Tablets

CDSCO approves 4 more Medical Device Testing Labs (MDTL)

DCGI gives nod to Intranasal C-19 booster dose

NPPA releases draft working sheets for ceiling price fixation of 954 formulations

USFDA gives nod for Levothyroxine Sodium For Injection

CDSCO gives nod to Dapagliflozin Tablets

Pharmacists deserve more recognition for their work

USFDA designates Cipla’s Goa plant as ‘OAI’

USFDA declines to approve this Lung Cancer drug

NPPA fixes Retail Price of 40 formulations: November 2022

IPC adds one IP Reference Standard & 20 new impurities to IP 2022

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news